146 related articles for article (PubMed ID: 25365263)
1. Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia.
Alachkar H; Mutonga MB; Metzeler KH; Fulton N; Malnassy G; Herold T; Spiekermann K; Bohlander SK; Hiddemann W; Matsuo Y; Stock W; Nakamura Y
Oncotarget; 2014 Dec; 5(23):12371-82. PubMed ID: 25365263
[TBL] [Abstract][Full Text] [Related]
2. Exploration of MELK as a downstream of Del-1 and druggable targets in triple-negative breast cancer.
Lee IH; Lee SJ; Kang B; Lee J; Jung JH; Park HY; Park JY; Park NJ; Kim EA; Kang J; Chae YS
Breast Cancer Res Treat; 2024 May; 205(1):181-191. PubMed ID: 38279017
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma.
Cigliano A; Pilo MG; Mela M; Ribback S; Dombrowski F; Pes GM; Cossu A; Evert M; Calvisi DF; Utpatel K
Medicina (Kaunas); 2019 Dec; 56(1):. PubMed ID: 31861475
[No Abstract] [Full Text] [Related]
4. Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.
Laha D; Grant RRC; Mishra P; Boufraqech M; Shen M; Zhang YQ; Hall MD; Quezado M; De Melo MS; Del Rivero J; Zeiger M; Nilubol N
J Exp Clin Cancer Res; 2022 Sep; 41(1):282. PubMed ID: 36151566
[TBL] [Abstract][Full Text] [Related]
5. Arrestin-3 interaction with maternal embryonic leucine-zipper kinase.
Perry NA; Fialkowski KP; Kaoud TS; Kaya AI; Chen AL; Taliaferro JM; Gurevich VV; Dalby KN; Iverson TM
Cell Signal; 2019 Nov; 63():109366. PubMed ID: 31352007
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for the regulation of maternal embryonic leucine zipper kinase.
Cao LS; Wang J; Chen Y; Deng H; Wang ZX; Wu JW
PLoS One; 2013; 8(7):e70031. PubMed ID: 23922895
[TBL] [Abstract][Full Text] [Related]
7. Targeting MELK improves PD-1 blockade efficiency in cervical cancer via enhancing antitumor immunity.
Wang D; Zou F; Li Y; Hu J; Gao L
Mol Ther Oncol; 2024 Mar; 32(1):200759. PubMed ID: 38596298
[TBL] [Abstract][Full Text] [Related]
8. Correction: Maternal Embryonic Leucine Zipper Kinase Is Associated with Metastasis in Triple-negative Breast Cancer.
Xie X; Chauhan GB; Edupuganti R; Kogawa T; Park J; Tacam M; Tan AW; Mughees M; Vidhu F; Liu DD; Taliaferro JM; Pitner MK; Browning LS; Lee JH; Bertucci F; Shen Y; Wang J; Ueno NT; Krishnamurthy S; Hortobagyi GN; Tripathy D; Van Laere SJ; Bartholomeusz G; Dalby KN; Bartholomeusz C
Cancer Res Commun; 2024 Jan; 4(1):236. PubMed ID: 38282551
[No Abstract] [Full Text] [Related]
9. MELK-a conserved kinase: functions, signaling, cancer, and controversy.
Ganguly R; Mohyeldin A; Thiel J; Kornblum HI; Beullens M; Nakano I
Clin Transl Med; 2015; 4():11. PubMed ID: 25852826
[TBL] [Abstract][Full Text] [Related]
10. EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner.
Kim SH; Joshi K; Ezhilarasan R; Myers TR; Siu J; Gu C; Nakano-Okuno M; Taylor D; Minata M; Sulman EP; Lee J; Bhat KP; Salcini AE; Nakano I
Stem Cell Reports; 2015 Feb; 4(2):226-38. PubMed ID: 25601206
[TBL] [Abstract][Full Text] [Related]
11. MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells.
Beke L; Kig C; Linders JT; Boens S; Boeckx A; van Heerde E; Parade M; De Bondt A; Van den Wyngaert I; Bashir T; Ogata S; Meerpoel L; Van Eynde A; Johnson CN; Beullens M; Brehmer D; Bollen M
Biosci Rep; 2015 Oct; 35(6):. PubMed ID: 26431963
[TBL] [Abstract][Full Text] [Related]
12. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
Inoue H; Kato T; Olugbile S; Tamura K; Chung S; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y; Park JH
Oncotarget; 2016 Mar; 7(12):13621-33. PubMed ID: 26871945
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.
Chung S; Kijima K; Kudo A; Fujisawa Y; Harada Y; Taira A; Takamatsu N; Miyamoto T; Matsuo Y; Nakamura Y
Oncotarget; 2016 Apr; 7(14):18171-82. PubMed ID: 26918358
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells.
Kato T; Inoue H; Imoto S; Tamada Y; Miyamoto T; Matsuo Y; Nakamura Y; Park JH
Oncotarget; 2016 Apr; 7(14):17652-64. PubMed ID: 26933922
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper Kinase.
Johnson CN; Adelinet C; Berdini V; Beke L; Bonnet P; Brehmer D; Calo F; Coyle JE; Day PJ; Frederickson M; Freyne EJ; Gilissen RA; Hamlett CC; Howard S; Meerpoel L; Mevellec L; McMenamin R; Pasquier E; Patel S; Rees DC; Linders JT
ACS Med Chem Lett; 2015 Jan; 6(1):31-6. PubMed ID: 25589926
[TBL] [Abstract][Full Text] [Related]
16. Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival.
Wang Y; Begley M; Li Q; Huang HT; Lako A; Eck MJ; Gray NS; Mitchison TJ; Cantley LC; Zhao JJ
Proc Natl Acad Sci U S A; 2016 Aug; 113(35):9810-5. PubMed ID: 27528663
[TBL] [Abstract][Full Text] [Related]
17. Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer.
Speers C; Zhao SG; Kothari V; Santola A; Liu M; Wilder-Romans K; Evans J; Batra N; Bartelink H; Hayes DF; Lawrence TS; Brown PH; Pierce LJ; Feng FY
Clin Cancer Res; 2016 Dec; 22(23):5864-5875. PubMed ID: 27225691
[TBL] [Abstract][Full Text] [Related]
18. Critical roles of non-histone protein lysine methylation in human tumorigenesis.
Hamamoto R; Saloura V; Nakamura Y
Nat Rev Cancer; 2015 Feb; 15(2):110-24. PubMed ID: 25614009
[TBL] [Abstract][Full Text] [Related]
19. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.
Feng M; Wang D; Grobler JA; Hazuda DJ; Miller MD; Lai MT
Antimicrob Agents Chemother; 2015 Jan; 59(1):590-8. PubMed ID: 25385110
[TBL] [Abstract][Full Text] [Related]
20. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
Wedzicha JA; Buhl R; Lawrence D; Young D
Respir Med; 2015 Jan; 109(1):105-11. PubMed ID: 25433954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
